The proteasome inhibitor bortezomib inhibits the release of NFκB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients

Clinical and Experimental Rheumatology

Volumn 27, Issue 1, 2009, Pages 92-98

  van der Heijden, Joost W ^a   Oerlemans, Ruud ^a   Lems, Willem F ^a   Scheper, Rik J ^a   Dijkmans, Ben A C ^a   Jansen, Gerrit ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Bortezomib; Cytokines; Methotrexate; NF B; Proteasome; Rheumatoid arthritis

Indexed keywords

BORTEZOMIB; CD28 ANTIGEN; CD3 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; EX VIVO STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; IC 50; LYMPHOCYTE ACTIVATION; MALE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; T LYMPHOCYTE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; APOPTOSIS; ARTHRITIS, RHEUMATOID; BORONIC ACIDS; CASE-CONTROL STUDIES; CYTOKINES; HUMANS; MALE; MIDDLE AGED; NF-KAPPA B; PILOT PROJECTS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; T-LYMPHOCYTES;

EID: 63049137443     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. GLICKMAN MH, CIECHANOVER A: The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
2. ROCK KL, YORK IA, GOLDBERG AL: Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 2004; 5: 670-7.
3. KLOETZEL PM, OSSENDORP F: Proteasome, and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004; 16: 76-81.
4. FIRESTEIN GS: NF-kappaB: Holy Grail for rheumatoid arthritis? Arthritis Rheum 2004; 50: 2381-6.
5. TAK PA, FIRESTEIN GS: NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11.
6. KARIN M, LIN A: NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3: 221-7.
7. ELLIOTT PJ, ZOLLNAR TM, BOERNCKE WH: Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 2003; 81: 235-45.
8. REINSTEIN E,PCIECHANOVER A: Narrative review: protein degradation and human diseases: The ubiquitin connection. Ann Intern Med 2006; 145: 676-84.
9. RAJKUMAR SV, RICHARDSON PG, HIDESHIMA T, ANDERSON KC: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23: 630-9.
10. NENCIONI A, GRUNEBACH F, PATRONE F, BALLESTRERO A, BROSSART P: Proteasome inhibitors: Antitumor effects and beyond. Leukemia 2007; 21: 30-6.
11. SHEN J, REIS J, MORRISON DC et al.: Key inflammatory signaling pathways are regulated by the proteasome. Shock 2006; 25: 472-84.
12. PARAMORE A, FRANTZ S: Bortezomib: Nat Rev Drug Discov 2003; 2: 611-2.
13. RICHARDSON PG, MITSIADES C, HIDESHIMA T, ANDERSON KC: Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006; 57: 33-47.
14. MITSIADES CS, TREON SP, MITSIADES N et al.: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple mycloma: Therapeutic applications. Blood 2001; 98: 795-804.
15. STRAUSS SJ, MAHARAJ L, HOARE S et al.: Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24: 2105-12.
16. ZHANG N, AHSAN MH, PURCHIO AF, WEST DB: Serum amyloid A-luciferase transgenic mice: Response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition. J Immunol 2005; 174: 8125-34.
17. PALOMBELLA VJ, CONNER EM, FUSELER JW et al.: Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998; 95: 15671-6.
18. NEUBERT K, MEISTER S, MOSER K et al.: The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-55.
19. GERARDS AH, DE LATHOUDER S, DE GROOT ER, DUKMANS BA, AARDEN LA: Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 1189-96.
20. MCINNES IB, SCHETT G: Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-42.
21. CHAUHAN D, CATLEY L, LI G et al.: A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8: 407-19.
22. MITRA-KAUSHIK S, HARDING JC, HESS JL, RATNER L: Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood 2004; 104: 802-9.
23. BLANCO B, PEREZ-SIMON JA, SANCHEZ-ABARCA LI et al.: Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006; 107: 3575-83.
24. VAN DER HEUDEN JW, DUKMANS BA, SCHEPER RJ, JANSEN G: Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs-from bench to bedside. Nat Clin Pract Rheumatol 2007; 3: 26-34.
25. EGERER K, KUCKELKORN U, RUDOLPH PE et al.: Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol 2002; 29: 2045-52.
26. EGERER T, MARTINEZ-GAMBOA L, DANKOF A et al.: Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjögren's syndrome. Arthritis Rheum 2006; 54: 1501-8.
27. PONNAPPAN S, OVAA H, PONNAPPAN U: Lower expression of catalytic and structural subunits of the proteasome contributes to decreased proteolysis in peripheral blood T lymphocytes during aging. Int J Biochem Cell Biol 2007; 39: 799-809.
28. WHEAT LM, KOHLHAAS SL, MONBALIU J et al.: Inhibition of bortezomib-induced apoptosis by red blood cell uptake. Leukemia 2006; 20: 1646-9.
29. PAPANDREOU CN, DALIANI DD, NIX D et al.: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108-21.
30. LEVEQUE D, CARVALHO MC, MALOISEL F: Review. Clinical pharmacokinetics of bortezomib. In Vivo 2007; 21: 273-8.
31. BERENSON JR, JAGANNATH S, BARLOGIE B et al.: Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005; 104: 2141-8.
32. BANG H, EGERER K, GAULIARD A et al.: Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007; 56: 2503-11.
33. SALEEM B, NIZAM S, EMERY P: Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol 2006; 24 (Suppl. 43): S-6.
34. KISSELEV AF, GOLDBFRG AL: Proteasome, inhibitors: from research tools to drug candidates. Chem Biol 2001; 8: 739-58.
35. NENCIONI A, GRUNEBACH F, PATRONE F, BALLESTRERO A, BROSSART P: The proteasome and its inhibitors in immune regulation and immune disorders. Crit Rev Immunol 2006; 26: 487-98.